MedPath

A Randomized Controlled Study of Conservative Treatment of Granulomatous Lobular Mastitis Combined With Psychiatric Disorders

Not Applicable
Conditions
Breast Diseases
Mastitis Granulomatous
Psychiatric Disorder
Interventions
Drug: conservative treatment
Registration Number
NCT05395949
Lead Sponsor
Wuhan University
Brief Summary

Granulomatous lobular mastitis (GLM) is a relatively rare chronic inflammatory disease of the breast in clinical practice. A small number of patients develop hyperprolactinemia during psychiatric drug treatment, and most of these patients are nulliparous. At present, there is no unified treatment mode at home and abroad, and surgery is generally the main treatment. GLM is a sterile inflammation, and glucocorticoids and methotrexate can effectively relieve clinical symptoms and even reach the standard of cure. In order to reduce the recurrence rate and protect the breast appearance as much as possible, we propose a conservative therapy. The purpose of this study was to compare this conservative therapy of granulomatous lobular mastitis with existing surgical treatment, and to compare the overall benefits of the two for patients with GLM. We aim to protect the breast appearance on the premise of low recurrence, improve the quality of life of GLM patients with psychiatric disorders .

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
Female
Target Recruitment
50
Inclusion Criteria
  • Patients aged 18 years or older with granulomatous lobular mastitis
  • Patients with Psychiatric Disorders;
  • Patients volunteered to participate in the study after informed consent.
Exclusion Criteria
  • Patients were diagnosed with mastitis with other definite etiology confirmed by pathology
  • Patients in acute exacerbation of mental illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Steroid combined with methotrexateconservative treatmentPrednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.
Primary Outcome Measures
NameTimeMethod
Recurrence rateUp to 1 years

Inflammatory changes, mass, abscess or fistula formation, nodular erythema of the upper and lower extremities and joint pain occurred in the ipilateral breast within one year after surgery was defined as recurrence.

Breast appearance and cosmetic effect scoreUp to 1 years

Refer to Harris standard to evaluate postoperative cosmetic effect. Specify the breast appearance and cosmetic effect rating table.

Secondary Outcome Measures
NameTimeMethod
recovery timeUp to 2 years

the timing of the disappearance of the symptoms including Inflammatory changes, mass, abscess or fistula formation, nodular erythema of the upper and lower extremities and joint pain occurred in the ipilateral breast

Trial Locations

Locations (1)

Zhongnan Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath